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Background: Poor adherence to asthma treatment is a well-recognised challenge and is asso-
ciated with increased morbidity, mortality and consumption of health care resources. This
study examined the impact of receiving a daily text message reminder on one’s cell phone
on adherence to asthma treatment.
Methods: A total of 26 subjects aged 18e45 years, with a clinical history of asthma and a posi-
tive methacholine challenge test (PD20  4 mmol) were randomised to receive, or to not
receive, a daily short message service (SMS) reminder on their cell phone to take their anti-
asthmatic medication. Inhaled corticosteroids to last for eight weeks and a prescription for
four additional weeks were given to the subjects. The primary outcome was adherence to
asthma treatment. Secondary outcomes were reimbursement of asthma medication, and
change in exhaled nitric oxide levels, lung function, and airway responsiveness.
Results: The absolute difference in mean adherence rate between the two groups after 12
weeks was 17.8%, 95% CI (3.2e32.3%), pZ 0.019. No significant differences were observed
between the two randomisation groups for the secondary outcomes.
Conclusion: Daily text message reminders are already after a short period of observation asso-
ciated with increased adherence to anti-asthmatic medication.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Sufficient asthma control means that the patient has
minimal symptoms, no or minimal use of reliever medi-
cation, no limitation of daily activities, normal lung
function, and few exacerbations.1 To achieve long-term13 9838; fax: þ45 3531 2179.
homsen).
9 Elsevier Ltd. All rights reservedcontrol of asthma a variety of approaches are needed such
as appropriate medication, patient education and lastly
sufficient adherence. Adherence is generally defined as
the extent to which patients take medications as
prescribed by their health care provider. Adherence to
treatment in chronic diseases is a well-recognised chal-
lenge. Studies have found adherence rates to asthma
treatment as low as 50%, which leads to poor asthma
control characterised by daily symptoms of breathless-
ness, decreased lung function, increased inflammation.
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forgetfulness to be one of the main reasons for their poor
adherence indicating an area with room for improve-
ment.2,3 Non-adherence is often defined as insufficient
intake of the prescribed medicine with an adherence rate
cut-off at 80%,4 but there is no consensus as to what
constitutes adequate adherence. As modern technology
has progressed over the years, this field is now being
studied as a possible means to improve adherence.
Reminder packaging has been shown to improve adher-
ence to self-administered long-term medications for some
time.5 Recent research now suggests increased adherence
to asthma treatment with modern technology devices,
such as audiovisual reminder functions, where an elec-
tronic audio alarm reminds patients when to take their
medication.6 Electronic patient diaries, where patients
daily report peak expiratory flow (PEF) measurements on
their cell phones, have also been tested as a possible
instrument to improve adherence, and so far with prom-
ising results.7,8 Internet as well as cell phone services,
including short message service (SMS), is being imple-
mented more and more in the public health care system e
especially by means of optimising communication
between health care providers and patients. This study
examined the impact of receiving a daily text message
reminder on one’s cell phone on the adherence to asthma
treatment.
Methods
Study design
The study was a follow-up investigation with three clinical
examinations at week 0, 4 and 12. At week 0 all patients
were given treatment with Seretide (inhaled corticoste-
roids, ICS and long acting b2-agonist, LABA, in combination)
1 dose twice daily. At week 4 the subjects were randomised
to either 1) receiving a daily SMS e a reminder to take their
asthma medication (the SMS group) or 2) not receiving
a SMS reminder (the control group). The SMS reminder was
sent daily at 10 a.m. on their cell phone in the following 8
weeks. All participants were informed of the aim of the
study and randomisation was done by means of automatic
computer generation of randomisation numbers in blocks of
six. Discos Seretide were given twice daily to all subjects
at week 0 and 4 (total treatment 60 days). Furthermore, at
week 4, all subjects were given a prescription for their
treatment in the remaining 4 weeks of the study (from
week 8 to 12). All participants were instructed to bring
their asthma medicine to the following visit for adherence
measurement where medicine dose-count on the discos
Seretide was noted (week 4 and 12). Furthermore, all
participants were instructed to start treatment on the day
of visit 1 and also not to take their medicine 12 hours
before the clinical examination at week 4 and 12. All
patients enrolled received a thorough education concern-
ing the necessity of ICS treatment in asthma and all were
provided with knowledge of the disease mechanisms and
correct inhaler technique. All three visits included an
interview conducted by the author, followed by measure-
ment of exhaled nitric oxide (eNO), lung function andairway responsiveness to inhaled methacholine. Further-
more, the first visit included a skin prick test. The scientific
ethical committee of Copenhagen, Denmark approved the
study (no. H-C-2007-0132) and written consent was
obtained from all participants before the first clinical
examination.
The primary study outcome was the mean adherence
rate to asthma treatment, whereas secondary outcomes
were reimbursement of asthma medication and change in
exhaled nitric oxide levels, lung function, and airway
responsiveness.
Study population
A total of 54 subjects responded to advertisements in free
local newspapers. The inclusion criteria were all of the
following: 1) A diagnosis of asthma based on a clinical
history and daily symptoms, 2) age between 18 to 45
years, and 3) a positive methacholine challenge test with
PD20 4 mmol. Exclusion criteria included other medical
co-morbidities and a smoking history of more than 10
packyears. After a screening session, 30 of the 54 subjects
met the inclusion criteria and were enrolled in the three-
month follow-up study. Of the 30 asthmatics, 26 subjects
were randomised at week 4 (SMS group, nZ 12 and
control group, nZ 14). A total of 22 subjects completed
the study at week 12 (SMS group, nZ 10 and control
group, nZ 12).
The asthma severity among the randomised subjects was
as follows: eight subjects (30.8%) were categorised as mild
persistent (GINA 2), 16 subjects (61.5%) as moderate
persistent (GINA 3) and two subjects (7.7%) were cat-
egorised as severe persistent (GINA 4).1 Before enrolment
into the study, nine subjects (34.6%) had used SABA as
monotherapy, nine subjects (34.6%) had used ICS (alone or
in combination with LABA and/or SABA) and the remaining
eight subjects (30.8%) had not used any treatment at all
over the last three months.
Exhaled nitric oxide
Exhaled nitric oxide (eNO) was measured using the Nitric
Oxide Analyzer (Niox, Solna, Sweden), which measures the
concentration of NO in the expired air. The participants
inhaled NO free air and exhaled for 10 s with a constant
expiratory flow. The procedure was repeated three times
and a mean concentration of NO (ppb) was calculated. NO
measurements were performed before any other assess-
ment of pulmonary function.9,10
Lung function measurement
Spirometric measurements of the forced vital capacity
(FVC) and the forced expiratory volume in 1 s (FEV1) were
used to assess airway limitations among the participants.
The FEV1 and FVC were measured using a 7-L dry wedge
spirometer (Vitalograph, Buckingham, UK). At least two
measurements of maximal expiratory manoeuvres from
total lung capacity to residual volume were performed. The
highest FEV1 and FVC were used in the analysis. Predicted
values of FEV1 and FVC were based on reference values
according to Nysom et al.11
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Airway responsiveness to inhaled methacholine was
measured using the method described by Yan et al.12 A
Morgan nebulizer generated the aerosols of the test solu-
tion. Each aerosol was inhaled through the mouth starting
with saline (0.9%) and followed by increasing doses of
methacholine until a cumulative dose of 7.8 mmol had been
reached. The response was measured by determining FEV1
twice 60 seconds after each inhalation. The test was
terminated when the maximum concentration had been
reached or when a 20% decline in FEV1 had occurred before
the end of the dosing regimen. If a 10% decrease in FEV1
occurred, the provocation was performed at half rate. A
positive test was defined as a PD20 4 mmol. The response
dose ratio (RDR) was calculated: RDRZ (DFEV1/
FEV1(baseline) 100)/PD20 (mmol).
Skin prick test and blood eosinophils
Skin prick tests were performed with a standard panel of
ten allergens consisting of birch, grass, mugwort, horse,
dog, cat, house dust mite (D. Pteronyssinus and D. Farinae)
and fungi (Alternaria and Cladosporium) (ALK-Abello,
Hoersholm, Denmark). A wheal diameter of at least 3 mm
was regarded as positive, and atopy was defined as a posi-
tive skin prick test to at least one of the ten allergens. The
number of eosinophils (109/L) in the peripheral blood was
measured in blood samples at week 0.
Short message service
The participants randomised to the SMS group received the
following short text message daily at 10 a.m. from week 4:
‘‘Remember to take your asthma medication morning andTable 1 Characteristics of two randomisation groups at enrolm
Variable SMS group (nZ 12) Cont
Male sex 6 (50.0) 8 (57
Age 34.4 30.7
Height (cm) 173.3 175.
Weight (kg) 89.5 81.8
BMI 30.1 26.5
Age at onset 17.8 16.7
Duration 16.9 15.6
Packyears 0.8 1.3
Eosinophils (109/L) 0.21 0.29
Atopy 9 (75) 12 (8
eNO (ppb) 32.6 45.3
FEV1 (L) 3.32 3.28
FVC (L) 4.38 4.27
FEV1% of predicted 84.5 80.0
FEV1/FVC 76.4 77.3
PD20 (mmol), median 0.75 1.00
LogRDR 1.59 1.59
ACQ, median 1.71 1.93
MiniAQLQ, median 5.67 5.47evening. From the Respiratory Unit’’. The service was
administered via the Internet by CIM mobility.
Medicine count and pharmacy reports
The medicine administration count on the inhaler device
was registered at week 4 and 12 and adherence rate was
registered as the percentage of the medicine actually taken
by the patients, calculated from the medicine dose-count
on the discos Seretide and the number of days between
clinical examinations: (60 dose-count)/2 days 100%.
Pharmacy reports were collected from www.sundhed.dk,
where all pharmaceutical transactions within the last two
years are registered. In the present study, the time to
collect the prescribed medicine was noted.Statistical analysis
The data were analysed with the statistical package SPSS
(SPSS Inc., Chicago, IL). Continuous data were analysed by
t-tests whereas categorical data were compared using chi
squared and Fisher’s exact tests. The Wilcoxon signed rank
test and the Mann-Whitney test was used to compare non-
parametric data. A p-value <0.05 was considered statisti-
cally significant.13Results
Descriptives
There were no significant differences between the basic
characteristics of the two randomisation groups at the time
of enrolment (Table 1). Furthermore, there was noent.
rol group (nZ 14) Total (nZ 26) P-value
) 14 (54) 0.72
32.2 0.22
0 174.2 0.64
85.3 0.28
28.1 0.14
17.2 0.82
16.2 0.78
1.1 0.59
0.26 0.14
6) 21 (81) 0.64
39.5 0.31
3.30 0.89
4.32 0.81
82.1 0.46
76.9 0.82
1.00 0.99
1.59 0.99
1.79 0.52
5.53 0.70
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Figure 1 Change in mean adherence rate in the SMS group
and the control group between week 4 and week 12.
SMS reminder and adherence to asthma treatment 169difference between the groups in their use of asthma
medication prior to enrolment (pZ 0.30).
Primary outcome
From week 4 to week 12 the mean adherence rate in the
SMS group increased from 77.9% to 81.5%; mean
changeZ 3.6%, 95% CI (8.5e15.7%), pZ 0.52, whereas
the mean adherence rate in the control group decreased
from 84.2% to 70.1%; mean changeZ14.2%, 95% CI
(24.2e4.1%), pZ 0.01 (Fig. 1). The absolute difference in
mean adherence rate between the two groups after 12
weeks was 17.8%, 95% CI (3.2e32.3%), pZ 0.019.
Secondary outcomes
We did not observe any significant differences in the
secondary outcomes between the SMS group and control
group after 12 weeks (Table 2). Notably, a total of 17 (65%) of
the randomised subjects had collected their prescribed anti-
asthmatic medication at the pharmacy at follow-up. Of
these, nine subjects were from the SMS group and eight
subjects were from the control group (pZ 0.68). Also, we
found no significant differences in the number of days for the
subjects in each group to collect their medicine; a median of
29 days (range 13 to 49 days) in the SMS group vs. a median of
32 days (range 13 to 50 days) in the control group (pZ 0.56).Table 2 Secondary outcomes in the two randomisation groups.
Variable Total (nZ 22) SMS group (nZ
Difference (95% CI) P-value Difference (95%
eNO (ppb) 19.4 (29.5e9.5) <0.001 18.0 (33.6e
FEV1% of predicted 5.66 (1.24e10.07) 0.015 3.28 (1.94e
FEV1/FVC 2.02 (0.49e4.54) 0.109 0.72 (1.89e
LogRDR 0.87 (1.17e0.57) <0.001 0.76 (1.18e
ACQ 0.73 (1.03e0.44) <0.001 0.87 (1.40e
MiniAQLQ 0.58 (0.27e0.90) <0.001 0.57 (0.05e1
P-value for test of differential effect in SMS and control group.During the study, we observed overall improvements in eNO
(p< 0.001), airway responsiveness (RDR) (p< 0.001) and
FEV1 (pZ 0.015). The change in these parameters were,
however, not differential in the two groups.
Discussion
This 12-week follow-up study showed that asthmatic
patients who receive a daily SMS reminder on their cell
phone remember to take, on average, about 18% more
doses of their anti-asthmatic medication compared with
asthmatic patients who do not receive such an SMS
reminder.
Improvement of the generally poor adherence rates in
treatment of asthma is essential to obtain adequate asthma
control. As demonstrated by Suissa et al. poor adherence to
asthma treatment is correlated with increased morbidity
and mortality and an increased consumption of health care
resources.6 A daily SMS reminder is thought to create
a higher awareness of asthma control and treatment and by
implementing this awareness in a patient’s daily routine the
adherent behaviour is improved. For example, forgetful-
ness has been reported by 30% of patients in recent studies
to be one of the main reasons for non-adherence.14 Non-
intentional and intentional non-adherence often co-exist in
the same individual, and guidelines advice a combination of
various interventions to achieve and sustain sufficient
adherence. All subjects in this study were thoroughly
instructed in the necessity of ICS treatment for asthma and
provided knowledge of the disease and correct inhaler
technique e all interventions known to be associated with
improved adherence to treatment.1 However, despite
frequent examinations during the 12-week study period,
these interventions together did not seem to be sufficient
in the control group, suggesting a general need for
a broader approach in improving adherence to treatment.
The effects of a daily SMS reminder on adherence appear
to be somewhat larger than the effects on the clinical
outcomes in the present study. To some extent, this was to
be expected, as modest amounts of non-adherence may
still leave patients within a well-treated therapeutic
window. Furthermore, as no consensus exists for what
constitutes adequate adherence, a poorer adherence may
still be sufficient for a short period of time to improve
clinical outcomes in steroid-naı¨ve or undertreated patients.
Some of the clinical outcomes are known to improve rather
quickly, i.e. eNO, after initiating treatment with ICS,
however it is difficult to stipulate the period of time it10) Control group (nZ 12) SMSZ control1)
CI) P-value Difference (95% CI) P-value
2.3) 0.029 20.6 (35.6e5.6) 0.012 0.795
8.50) 0.189 7.65 (0.22e15.07) 0.045 0.318
3.33) 0.548 3.11 (1.28e7.50) 0.147 0.337
0.35) 0.003 0.99 (1.52e0.46) 0.003 0.453
0.34) 0.005 0.62 (1.01e0.23) 0.005 0.392
.10) 0.035 0.59 (0.13e1.05) 0.016 0.961
170 U. Strandbygaard et al.takes - and how much medicine not to be taken for the
individual patient e before the initial improvement in
clinical outcomes begins to revert. Seasonal variation in
symptoms followed by changeable needs in medication
regimens does not simplify these questions. Charles et al.
demonstrated a significant improvement in adherence to
treatment with an audiovisual reminder device, but at the
end of the 6-month study period no differences in clinical
outcomes (PEF) between the groups were observed.6 In
that study the proportion of adherent subjects (80% of
their medication taken) after 6 months were 88.6% in the
study group compared to 39.1% in the control group. PEF
may therefore be a too stable measure, whereas eNO
probably would have shown differences even when only 39%
were taken their medication. The low proportion of
adherent subjects in the control group in the study indi-
cates, that after a short period of increased adherence
among all patients and improvements in clinical outcome e
as commonly seen in the beginning of a clinical trial e it
may take a period of more than 6 months before the initial
improvements has reverted in non-adherent subjects.
The time to collect the prescribed medicine at the
pharmacy was longer in the control group, compared with
the study group, however, not statistically significant, and
it would therefore have been interesting to evaluate the
collecting time over a longer period of time. The adherence
rate in the control group was reduced significantly during
the study period, and it may only be a matter of time
before this also affects the adherent behaviour regarding
the reimbursement of medication. Firstly, and most obvi-
ously, because the patients do not require refill as often
because of lower adherence rates equal to a lower
consumption of medicine and secondly, due to a generally
poor adherent behaviour with minor focus on preventative
asthma treatment. Furthermore, it is not uncommon among
non-adherent patients to have a high use of SABA and
low use of ICS. A Danish study described undertreatment
among almost 50% of asthmatic patients with persistent
asthma, receiving only SABA or LABA as monotherapy.15
Therefore, together with the collecting time of prescribed
medication, the type of medicine collected (SABA, LABA
and/or ICS) is also an important factor to keep in mind.
Overall, the perception of receiving a daily SMS was
positive (data not shown), although the majority found the
SMS receiving time at 10 o’clock in the morning unsuitable,
which implies room for improvement in further studies. It
would be advisable to adjust the SMS receiving time indi-
vidually to each patient to optimise the effect, as patients
differ greatly in daily routines. A daily SMS reminder is,
thus, easily implemented within clinical settings, as most
adult patients have a cell phone.
This study had a limited sample size and a short follow-
up period, therefore further studies with more participants
and a longer follow-up are required before any unambig-
uous conclusions and a cost-benefit profile can be made
regarding the effect on clinical outcomes. A potential
adaptation to the SMS message may also be observed during
a study period longer than three months. However, most of
the participants in the intervention group noticed the SMS
daily at receiving time, but stopped reading it after some
weeks, indicating that over time the function of an SMS is to
be compared with a simple alarm clock on a cell phone,creating a higher awareness of asthma control in the
patient’s adherent behaviour. In this study the adherence
measurement method has the limitation of dose-dumping,
where participants could empty their medicine devices
prior to the visits. Hence, the validity of adherence
measurement was based upon participant credibility
regarding possible dose-dumping on the discos Seretide,
and is a possible limitation of the study. We found no reason
to believe that the validity of adherence differed between
the intervention and control group based upon interviews
with the participants at week 12 and furthermore as both
study groups were aware of the aim of the study. However,
by implementing a smartinhaler as done by Charles et al.,
this limitation would be reduced in future studies.
In conclusion, a daily SMS reminder was found to have
a significant effect on adherence to asthma treatment. Our
findings expand upon those described by Charles et al.
where an audiovisual reminder device significantly
improved adherence to treatment.6 As non-adherence is
not only problematic in respect to asthma treatment, it
also opens the possibility for a daily SMS reminder to
improve adherence to treatment regimens across a larger
spectrum of chronic diseases.
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